abstract |
The present invention comprises a stable and non-toxic coenzyme Q10 formulation suitable for intravenous administration to an animal to produce clinically effective blood levels of coenzyme Q10. Clinically effective blood levels of coenzyme Q10 are generally agreed to be between about 2 ug/ml and about 4 ug/ml. The formulation consists essentially of a clinically accepted fatty emulsion having an oil phase and coenzyme Q10 dissolved in the oil phase. The formulation preferably contains coenzyme Q10 at a level between about 7.5 ug/ml and about 30 ug/ml. The clinically accepted fatty emulsion comprises at least one vegetable oil, preferably corn oil, peanut oil, safflower oil, olive oil or soybean oil. |